Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and safety of Novartis meningococcal B recombinant vaccine on a 0, 2-month schedule in at-risk adults
2012-005815-25Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of meningococcal group B vaccine (recombinant, adsorbed) in meningococcal disease, sponsored by Novartis. Primary endpoint: Serum bactericidal antibody response against indicator strains. Started May 2013; status: completed.
02
Drugs
meningococcal group B vaccine (recombinant, adsorbed)
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2012-005815-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005815-25.